At present, chimeric antigen receptor (CAR)-modified T or NK cell (CAR-T/NK) therapy has been proven to be an effective tumor therapy, especially the successful application of CD19-targeted CAR-T/NK cell therapy in certain leukemia and lymphoma8, 9. Here, CD19 is linked to neoplasm.